Introduction {#sec1}
============

First reported by Alois Alzheimer in 1906, Alzheimer's disease (AD) is a form of dementia that currently affects nearly 46.8 million people worldwide, and about 10% of those are in United States alone.^[@ref1]^ Such a huge number of patients create numerous challenges for the society.^[@ref2]^ Because the acetyl cholinesterase inhibitor drugs tacrine, donepezil, rivastigmine and galantamine, and *N*-methyl-[d]{.smallcaps}-aspartate-receptor antagonist memantine were approved by the Food and Drug Administration (FDA) in 1990's with the last being in 2003, not significant progress has been witnessed in the last decade. Though some secretase inhibitors, immunotherapeutics, metal chelators, and tau aggregation inhibitors have been through to some phases of clinical testing, most of them could not reach advanced stages and very few progressed to phase III trials and later failed owing to a number of reasons.^[@ref3]−[@ref9]^ Amongst a plethora of factors reported playing roles in the etiology of the disease, accumulation of amyloid β (Aβ) plaques is the most widely accepted phenomenon.^[@ref10]−[@ref12]^ Though inhibition of Aβ aggregation currently remains one of the viable target for the global scientific community,^[@ref13],[@ref14]^ the designing of anti-amyloidogenic agents is no exception in being associated with own variety of challenges.^[@ref15]^ A number of small molecules have shown potential to disrupt the Aβ aggregation process and few even progressed to clinical trials; however, their nonspecific mechanism of action have restricted their further developments.^[@ref16]−[@ref18]^ Bexarotene, a small molecule and an USFDA approved drug for cancer, is recently reported to block initial nucleation steps of Aβ assembly and delay the onset of toxic aggregates has completed phase II clinical trials.^[@ref19]^

Because peptide fragments are specific in their binding with their parent peptide, the very initial focus on the design of Aβ inhibitors revolved around the sequence derived peptide fragments of Aβ itself. Pioneer work in this regard mentions the inhibitory effects of a pentapeptide KLVFF (Aβ~16--20~) fragment derived from the central hydrophobic sequence of full-length peptide. Since then, the following one and a half decade focused on the design of inhibitors based on the modification of this pentapeptide sequence. As recently reviewed by Han and He,^[@ref15]^ a number of modifications such as introduction of [d]{.smallcaps}-amino acids and other unnatural residues, incorporation of hydrophilic oligomers at ends, retro-inversion, C-terminal amidation, and use of β-sheet interrupting residues were reported to exhibit anti-Aβ aggregation properties.^[@ref20]−[@ref25]^ Modified peptides such as SEN304 have undergone preclinical studies and PPI-1019 and iAβ5 were tested in phase II clinical trials; however, the studies were halted.^[@ref26],[@ref27]^ An N-methylated pentapeptide, SEN-606, is currently in clinical trials.^[@ref28]^ Gozes and co-workers reported an octapeptide, NAPVSIPQ (NAP), derived from activity-dependent neuroprotective protein that interfered with Aβ self-assembly and disaggregated preformed fibrils.^[@ref29]^ NAP was also found effective against mild cognitive impairment in phase II trials; however, it failed to show efficacy for progressive supranuclear palsy in a phase III trial.^[@ref30],[@ref31]^ A naturally occurring dipeptide, carnosine, was reported as a very effective Aβ aggregation lowering agent at 10 μM.^[@ref32]^ Another designed dipeptide ([d]{.smallcaps}-Trp-Aib-OH) was proven to be a promising inhibitor.^[@ref33]^ A peptide D3 exhibited high binding affinity toward Aβ and directed the equilibrium toward nontoxic aggregates.^[@ref34]^ D3 and some of its derivatives have undergone phase-II clinical trials and may be candidates for advanced clinical trials.^[@ref35],[@ref36]^

Fragments Aβ~31--42~, Aβ~38--42~, and Aβ~39--42~ derived from the hydrophobic C-terminus region were found to reduce the Aβ aggregation significantly.^[@ref37]^ A recent report investigated the inhibitory effects of pentapeptides derived from the fragment Aβ~38--42~.^[@ref38]^ A number of peptides were discovered to exhibit significant to complete inhibition of Aβ~1--42~ aggregation. In another study, N-methylation performed on the hexapeptide fragment, Aβ~32--37~ was shown to afford efficient inhibitors of Aβ aggregation.^[@ref39]^ By exploring the same fragment Aβ~32--37~, a hexapeptide was identified to completely abrogate Aβ toxicity at sub-micromolar concentrations.^[@ref40]^

In continuation of our studies on the design of new inhibitors of Aβ fibrillation, herein, we describe the synthesis of new peptides utilizing further the relatively less explored C-terminus region of Aβ. Synthesis was followed by biological evaluation of the new peptides for their potential activity against Aβ fibrillation. Primary screening by MTT cell culture assay was followed by the ThT fluorescence assay for the selected peptides. Further, we performed secondary structural analysis by circular dichroism (CD) spectroscopy and morphological examination of Aβ aggregates by electron microscopy to confirm the inhibitory activity of the best tetrapeptide **20**. Amino acid scan on the tetrapeptide fragment Aβ~39--42~ was performed, wherein we independently replaced all four amino acid residues of the sequence by their isosteric physico-chemically analogous counterparts. Using solid-phase peptide synthesis (SPPS) protocol, 43 new peptides were synthesized by Fmoc chemistry using automated peptide synthesizer. A general route for the synthesis of tetrapeptides exemplified by peptide **20** has been depicted in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. To start with, Wang resin with preloaded C-terminus amino acid was first swelled and the Fmoc group was removed by 20% piperidine in dimethylformamide (DMF). Next, the resin with the free amino group was coupled with the sequential amino acids required to synthesize the desired peptide sequence, in the presence of the coupling reagent *O*-(benzotriazol-1-yl)-*N*,*N*,*N*′,*N*′-tetramethyluronium tetrafluoroborate (TBTU) or 1-\[bis(dimethylamino)-methylene\]-1*H*-1,2,3-triazolo\[4,5-*b*\]pyridinium-3-oxid hexafluorophosphate (HATU) and base *N*,*N*-diisopropylethylamine (DIEA), in DMF for 2.5 h. Kaiser's test was performed to routinely monitor the coupling reaction. Once the peptide with the desired sequence was obtained, the Fmoc group at the N-terminus was removed with 20% piperidine, and peptide was cleaved from the resin by using 95% trifluoroacetic acid (TFA) in triisopropylsilane (TIPS) and water. The so-obtained crude peptides were purified and analyzed for purity by using reverse-phase high-performance liquid chromatography (HPLC).

![General Synthetic Route Exemplified by Peptide **20**\
Reagents and conditions: (i) 20% piperidine, DMF, 15 min; (ii) Fmoc-Ile-OH, TBTU, DIEA, DMF, 2.5 h; (iii) Fmoc-Aib-OH, HATU, DIEA, DMF, 2.5 h; (iv) Fmoc-Val-OH, HATU, DIEA, DMF, 2.5 h; (v) TFA, TIPS, water, 2.5 h.](ao-2018-01522t_0006){#sch1}

Results and Discussion {#sec2}
======================

MTT Cell Viability Study {#sec2.1}
------------------------

The newly synthesized tetrapeptides were first tested for their Aβ aggregation inhibitory potential by MTT cell culture assay. In the initial screening, performed to evaluate the synthesized tetrapeptides against the self-assembly and toxicity of Aβ peptides, a number of peptides were observed to rescue PC-12 cells from the Aβ aggregation-related toxicity. Considering the cell viability of untreated cells as 100%, only 70% cells were found to be viable when treated with 2 μM of Aβ~1--42~. The tetrapeptide (**1**, Val-Val-Ile-Ala), previously reported active against the aggregation of Aβ~1--42~ peptide was found to exhibit significant inhibition activity in this study as well. When tetrapeptide **1** (20 μM) was co-incubated with Aβ~1--42~, about 88% cells were found to be viable, corresponding to about 60% inhibition of Aβ toxicity. In the presence of four of the tetrapeptides, **18** (Val-[d]{.smallcaps}-Pro-Ile-Ala), **20** (Val-Aib-Ile-Ala), **24** (Aib-Aib-Ile-Ala), and **25** (Pro-Pro-Ile-Ala), cell viabilities were significantly improved. The tetrapeptide **20** (20 μM) was found to completely rescue PC-12 cells against Aβ~1--42~ toxicity, whereas in the presence of peptides **18**, **24**, and **25** about 89, 92, and 97% cells were found to be viable at 20 μM concentration ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}). Complete restoration of cell viability in the presence of peptide **20** indicates total inhibition of Aβ~1--42~ aggregation and toxicity. Four other tetrapeptides, **16** (20 μM, Val-[d]{.smallcaps}-Ile-Ile-Ala), **19** (20 μM, Val-Pro-Ile-Ala), **32** (2 μM, Val-Val-[d]{.smallcaps}-Pro-Ala), and **42** (20 μM, Val-Val-Ile-Ile), showed only slight improvements in cell viabilities and showed inhibition of amyloid toxicity in the range of only 20--40%. However, the peptide **20**, found to completely prevent Aβ~1--42~ aggregation, did not show inhibition toward Aβ~1--40~ toxicity for PC-12 cells (data not shown). The cell viabilities in the co-presence of either of these peptides were no different from those where PC-12 cells were incubated with Aβ~1--40~ alone. Cell viability data correspondingly converted to percentage Aβ~1--42~ inhibition values for the tested tetrapeptide analogues have been compiled in [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}.

###### Cell Viabilities and Percentage Inhibition of Aβ~1--42~ Toxicity by Tetrapeptides[a](#t1fn1){ref-type="table-fn"}

                                                test concentrations                               
  ----------- --------------------------------- --------------------- ------ ------ ------ ------ ------
  **1**       Val-Val-Ile-Ala                   88.0                  79.0   72.4   60.0   30.0   8.0
  **2**       [d]{.smallcaps}-Val-Val-Ile-Ala   71.2                  70.7   69.5   9.0    5.0    4.0
  **3**       [d]{.smallcaps}-Ala-Val-Ile-Ala   70.0                  70.0   70.0   0      0      0
  **4**       [d]{.smallcaps}-Leu-Val-Ile-Ala   70.6                  70.0   70.0   2.0    0      0
  **5**       Leu-Val-Ile-Ala                   70.0                  70.0   70.0   0      0      0
  **6**       [d]{.smallcaps}-Ile-Val-Ile-Ala   70.0                  70.0   70.0   0      0      0
  **7**       Ile-Val-Ile-Ala                   70.6                  70.9   70.0   2.0    3.0    0
  **8**       [d]{.smallcaps}-Pro-Val-Ile-Ala   71.2                  72.7   71.5   4.0    9.0    5.0
  **9**       Pro-Val-Ile-Ala                   70.0                  70.0   70.0   0      0      0
  **10**      Aib-Val-Ile-Ala                   73.9                  72.7   70.3   13.0   9.0    1.0
  **11**      Nva-Val-Ile-Ala                   70.0                  70.0   70.0   0      0      0
  **12**      Val-[d]{.smallcaps}-Val-Ile-Ala   70.0                  70.0   70.0   0      0      0
  **13**      Val-[d]{.smallcaps}-Ala-Ile-Ala   70.0                  70.0   70.0   0      0      0
  **14**      Val-[d]{.smallcaps}-Leu-Ile-Ala   70.3                  70.0   71.5   1.0    0      5.0
  **15**      Val-Leu-Ile-Ala                   73.9                  70.0   70.0   13.0   0      0
  **16**      Val-[d]{.smallcaps}-Ile-Ile-Ala   78.1                  76.0   76.0   27.0   20.0   20.0
  **17**      Val-Ile-Ile-Ala                   70.0                  70.0   70.0   0      0      0
  **18**      Val-[d]{.smallcaps}-Pro-Ile-Ala   89.2                  76.0   72.1   64.0   20.0   7.0
  **19**      Val-Pro-Ile-Ala                   77.2                  75.1   74.8   24.0   17.0   16.0
  **20**      Val-Aib-Ile-Ala                   100                   76.6   70.0   100    22.0   0
  **21**      Val-[d]{.smallcaps}-Phe-Ile-Ala   70.0                  71.5   70.0   0      5.0    0
  **22**      Val-Phe-Ile-Ala                   70.0                  69.5   69.2   8.0    4.0    3.0
  **23**      Val-Nva-Ile-Ala                   71.2                  70.7   69.5   9.0    5.0    4.0
  **24**      Aib-Aib-Ile-Ala                   91.9                  75.4   73.9   73.0   18.0   13.0
  **25**      Pro-Pro-Ile-Ala                   97.0                  81.7   74.2   90.0   39.0   14.0
  **26**      Val-Val-[d]{.smallcaps}-Ile-Ala   70.0                  70.0   70.0   0      0      0
  **27**      Val-Val-[d]{.smallcaps}-Ala-Ala   73.3                  70.0   70.0   11.0   0      0
  **28**      Val-Val-[d]{.smallcaps}-Leu-Ala   73.0                  70.6   70.0   10.0   2.0    0
  **29**      Val-Val-Leu-Ala                   70.0                  70.0   73.0   0      0      10.0
  **30**      Val-Val-[d]{.smallcaps}-Val-Ala   70.0                  70.0   70.0   0      0      0
  **31**      Val-Val-Val-Ala                   70.9                  70.0   70.0   3.0    0      0
  **32**      Val-Val-[d]{.smallcaps}-Pro-Ala   76.3                  77.8   78.1   21.0   26.0   27.0
  **33**      Val-Val-Pro-Ala                   70.9                  70.0   70.0   3.0    0      0
  **34**      Val-Val-Aib-Ala                   73.3                  70.0   70.3   11.0   0      1.0
  **35**      Val-Val-[d]{.smallcaps}-Phe-Ala   72.7                  73.0   71.2   9.0    10.0   4.0
  **36**      Val-Val-Phe-Ala                   70.0                  70.0   70.0   0      0      0
  **37**      Val-Val-Nva-Ala                   70.3                  70.0   70.0   1.0    0      0
  **38**      Val-Val-Nle-Ala                   70.0                  70.0   70.0   0      0      0
  **39**      Val-Val-Ile-[d]{.smallcaps}-Ala   71.2                  70.0   70.0   4.0    2.0    0
  **40**      Val-Val-Ile-Val                   72.7                  73.9   71.2   9.0    13.0   4.0
  **41**      Val-Val-Ile-Leu                   70.0                  70.0   70.0   0      0      0
  **42**      Val-Val-Ile-Ile                   78.7                  78.1   77.2   29.0   27.0   24.0
  **43**      Val-Val-Ile-[d]{.smallcaps}-Phe   71.2                  70.0   70.0   4.0    0      0
  **44**      Val-Val-Ile-Phe                   70.0                  70.0   70.0   0      0      0
  control                                       100                                                
  Aβ~1--42~                                     70.0                                               

The final concentration ratios of Aβ and test peptides were kept as 1:1, 1:5, and 1:10. Experiments were performed in triplicates (*n* = 3). Blank ODs were subtracted from each sample OD and the triplicate ODs were averaged. In a subset of triplicate wells, SD values ranged 1.35--4.98. Aib, aminoisobutyric acid; Nva, norvaline; Nle, norleucine.

Structure--Activity Relationship {#sec2.2}
--------------------------------

On the basis of the inhibitory activities shown by tetrapeptide derivatives in the cell viability assay, a structure--activity relationship was established. For the purpose of a start point, the inhibition activity shown by peptide **1** (60%, 20 μM) was taken as a reference. Residue Ile~41~ of the tetrapeptide (Val~39~-Val~40~-Ile~41~-Ala~42~) was found to be crucial for its activity and substitutions by residues such as [d]{.smallcaps}-Ile, [d]{.smallcaps}/[l]{.smallcaps}-Leu, [d]{.smallcaps}/[l]{.smallcaps}-Pro, [d]{.smallcaps}/[l]{.smallcaps}-Phe, [d]{.smallcaps}/[l]{.smallcaps}-Val, aminoisobutyric acid (Aib), Nva, Nle, and [d]{.smallcaps}-Ala at this position resulted in the loss of inhibitory activity. None of the peptides designed by substitution at Ile~41~ showed more than 30% inhibition of Aβ aggregation. Also, the substitution at the Val~39~ by residues such as Aib, Nva, [d]{.smallcaps}/[l]{.smallcaps}-Pro, [d]{.smallcaps}/[l]{.smallcaps}-Ile, [d]{.smallcaps}/[l]{.smallcaps}-Leu, [d]{.smallcaps}-Ala, and [d]{.smallcaps}-Val did not result into significant activity. Substitutions at the next residue (Val~40~) by [d]{.smallcaps}-Pro (Val-[d]{.smallcaps}-Pro-Ile-Ala, **18**) afforded a peptide that showed considerable inhibition (64%) of Aβ fibrillation, whereas the peptide obtained by substitution Val~40~ → Aib (Val-Aib-Ile-Ala, **20**) exhibited complete inhibition of Aβ fibrillation. However, other replacements by [d]{.smallcaps}-Val, [d]{.smallcaps}/[l]{.smallcaps}-Leu, [d]{.smallcaps}/[l]{.smallcaps}-Pro, [d]{.smallcaps}/[l]{.smallcaps}-Phe, [d]{.smallcaps}/[l]{.smallcaps}-Ile Aib, Nva, and [d]{.smallcaps}-Ala at this position resulted in inactive peptides. The substitutions at the C-terminus residue (Ala~42~) by Val, Leu, [d]{.smallcaps}/[l]{.smallcaps}-Phe, Ile, and [d]{.smallcaps}-Ala also did not yield any compound showing significant inhibition toward Aβ polymerization. By utilizing the known anti-β-sheet property of Aib and Pro residues, two more peptides \[Aib-Aib-Ile-Ala (**24**) and Pro-Pro-Ile-Ala (**25**)\] were designed and synthesized by replacing both Val~39~ and Val~40~ amino acids of the peptide **1**, simultaneously. These peptides proved to be good inhibitors (73% inhibition, **24**) and (90% inhibition, **25**) of amyloid aggregation. Because most of the positive substitutions (active peptides) were obtained by replacement of residues in the lead peptide by Aib and Pro, such an analysis supports the widely accepted β-sheet breaking capabilities of these residues. Specific interaction of the best inhibitor tetrapeptide (**20**) with the last two residues (Ile~41~ and Ala~42~) in Aβ~1--42~ is evidenced by its lack of activity against the smaller aggregating peptide Aβ~1--40~.

Thioflavin T (ThT) Fluorescence Study {#sec2.3}
-------------------------------------

Three best tetrapeptides, **20**, **24**, and **25**, showing amyloid-β toxicity inhibition in the range of 73--100%, in the cell viability assay, were further studied by ThT fluorescence assay. Upon co-incubation of tetrapeptides **20**, **24**, and **25** with the Aβ~1--42~ peptide, remarkable reduction in the ThT fluorescence was observed. Graphical representation of the relative ThT fluorescence, for the Aβ~1--42~ incubated alone, or plus the tetrapeptides is described in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}.

![Graphical demonstration of the effects of tetrapeptides **20**, **24**, and **25** on Aβ~1--42~ aggregation-mediated ThT fluorescence. ThT dye alone is represented as control while amyloid peptides incubated along with the dye are shown as Aβ~1--42~. Aβ~1--42~ was taken as 2 μM and the tetrapeptides **20**, **24**, and **25** were kept in ratios of 1:1, 1:5, and 1:10 (Aβ/test peptides) in the final incubated solutions. Sequential bars describe the co-incubated inhibitor peptides (indicated by numbers), with the Aβ peptide and ThT dye. Error bars represent mean ± SD (*n* = 3). Data were analyzed by one-way ANOVA test followed by Dunnett's multiple comparison test (ns---non significant, ^\$^*p* \< 0.05, ^\#^*p* \< 0.01, \**p* \< 0.001, vs Aβ) using software (GraphPad Prism, ISI, San Diego, CA). Experiments were performed in triplicates (*n* = 3). Blank values were subtracted from that of sample fluorescence and triplicates were averaged. In a subset of triplicate wells, SD values ranged 1.34--6.38.](ao-2018-01522t_0001){#fig1}

ThT dye alone (control) exhibited relative fluorescence unit (RFU) of 30%. In the presence of inhibitor tetrapeptides, RFU values did not deviate much from control and were quite close to the dye alone values. Such as in the presence of the peptide **20**, RFU value of 31.4% (20 μM) was observed. Likewise, tetrapeptides **24** and **25** co-incubated samples showed RFU values of 42.6 and 38.4% at 20 μM, respectively. Diminution of ThT fluorescence upon co-incubation of tetrapeptides **20**, **24**, and **25** with Aβ~1--42~ peptide supports the results of MTT assay for their inhibitory activity toward the prevention of Aβ~1--42~ self-assembly. However, similar to what was observed in the MTT assay, the tetrapeptides did not show inhibitory activity against the Aβ~1--40~ peptide (data not shown). The RFU values similar to that of Aβ~1--40~ alone point toward the formation of Aβ aggregates that indicates the inefficiency to inhibit the Aβ~1--40~ peptide aggregation.

Tetrapeptide **20** (Val-Aib-Ile-Ala) was further studied in a time-dependent manner and ThT fluorescence was measured at regular intervals for 7 days. ThT dye was incubated with aggregating peptide Aβ~1--42~ alone or plus the inhibitor peptide **20** so as to result into final solution concentrations in the ratio of 1:10 (Aβ/peptide **20**). When the ThT dye was incubated with Aβ~1--42~ alone, remarkable enhancement in the fluorescence was observed indicating the presence of large Aβ~1--42~ aggregates. After a slow rise in fluorescence intensity for initial 12 h, ThT fluorescence showed an exponential phase and reached saturation at about 120 h. Compared with the Aβ~1--42~ alone, ThT fluorescence was significantly reduced in the co-presence of the inhibitor peptide **20**. Only 43.4% RFU was observed when measured at 12 h. The subsequent measurements at various intervals showed even lesser values of RFUs. At 24 h, 3 days, 5 days, and 7 days after co-incubation of peptide **20** with Aβ~1--42~, relative fluorescence values of 6, 4, 10.9, and 11.4% were observed, respectively ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). Because ThT fluorescence is a direct indicator of the amyloid aggregation state, the reduction in the fluorescence demonstrates the inhibitory activity of tetrapeptide **20** toward Aβ~1--42~ aggregation. Thus, peptide **20** retained its inhibitory effects on the Aβ~1--42~ aggregation even after prolonged incubation. Hence, the results of the fluorescence assay have been found in good agreement and correlated well with those obtained in the MTT-based assay.

![Time-dependent studied inhibitory effects of tetrapeptide **20** on Aβ~1--42~ aggregation. Red line represents the Aβ~1--42~ aged alone, whereas Aβ~1--42~ peptide co-incubated with peptide **20** is shown in green. The aggregating peptide Aβ~1--42~ (2 μM) and inhibitor peptide **20** (20 μM) were taken in the final solution concentrations in the ratio of 1:10 (Aβ/peptide **20**). Error bars represent mean ± SD (*n* = 3). Data were analyzed by *t*-test (^\$^*p* \< 0.05, ^\#^*p* \< 0.01, \**p* \< 0.001, vs Aβ~1--42~) using software GraphPad Prism, ISI, San Diego, CA. Each experiment was performed in triplicates (*n* = 3) and triplicates were averaged. In a subset of triplicate wells, SD values ranged 0.22--1.32.](ao-2018-01522t_0002){#fig2}

Circular Dichroism Spectroscopy {#sec2.4}
-------------------------------

Under abnormal conditions, Aβ peptides undergo conformational changes and aggregates in the form of cross-β-sheet structure. Such a transition in the conformation from a mixture of various secondary structures toward β-sheet can be estimated quantitatively by using CD spectroscopy.^[@ref41]^ Tetrapeptide **20** (Val-Aib-Ile-Ala) was studied for its inhibitory effects on the conformational transition of Aβ~1--42~ peptide. Aβ and the inhibitor tetrapeptide **20** were mixed in a ratio of 1:5 and incubated for 12 h (*t*~12h~) before the secondary structure analysis was performed. As shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, Aβ~1--42~ aged alone for 12 h, shows an increase in the β-sheet content as evident by the development of a broad negative peak at 217--218 nm. Initial (*t*~0h~) secondary structure analysis of Aβ~1--42~ yielded a mixture of 9.5% of β-sheet, while being 61.8% in random coil and 28.7% β-turn forms. However, at 12 h of incubation, β-sheet component was increased to 47.1%, with the random coil reduced to 42.3%. To analyze secondary structure of Aβ~1--42~ peptide in the presence of inhibitor peptide **20**, inhibitor spectrum was subtracted from that of inhibitor-treated Aβ~1--42~.

![Effects of peptide **20** on the conformational transition of Aβ~1--42~ studied by CD spectroscopy. Aβ~1--42~ and the inhibitor tetrapeptide **20** were mixed in a ratio of 1:5 and incubated for 12 h (*t*~12h~) before the secondary structure analysis was performed. Shown in black and red are the CD spectra of Aβ~1--42~ at *t*~0h~ and *t*~12h~, respectively. Blue line shows the CD spectra of Aβ~1--42~ peptide co-incubated with peptide **20** at 12 h.](ao-2018-01522t_0003){#fig3}

Upon co-incubation with peptide **20** for 12 h (*t*~12h~), Aβ~1--42~ exhibited only 14.2% of β-sheet conformation while occupying 58.5% of random coil form. As evident from [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}, the disappearance of minima at 217 nm in the co-presence of inhibitor peptide **20** is a direct indication of the inhibitory activity of the tetrapeptide **20**.

Transmission Electron Microscopy (TEM) {#sec2.5}
--------------------------------------

Morphological examination of the Aβ~1--42~ aggregates in the co-presence of tetrapeptide **20** (Val-Aib-Ile-Ala) was performed by TEM. Scanning TEM (STEM) was further utilized to investigate shapes and appearance of Aβ~1--42~ assemblies. Peptide **43** (Val-Val-Ile-[d]{.smallcaps}-Phe, inactive in MTT assay) was taken as a negative control. An extensive network of long, cylindrical rod-like aggregates was observed when Aβ~1--42~ was aged alone. No fibril ends were observed in consecutive images \[[Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}A, high-resolution TEM (HRTEM) and [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}A, STEM\]. While upon co-incubation with peptide **20**, no such aggregates were formed ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}B, HRTEM and [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B, STEM). Only small irregular sized particles were detected. Peptide **20** also did not exhibit any self-aggregation when incubated alone under similar conditions ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}C, HRTEM and [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}C, STEM). TEM images of peptide **20** alone showed only scarcely spread small structures.

![Visual investigation of the aggregation of Aβ~1--42~ peptide in the presence of tetrapeptides **20** and **43** by HRTEM. Aβ~1--42~ and tetrapeptides **20** and **43** were mixed for a concentration ratio of 1:5 (Aβ~1--42~/test peptides) and incubated at 37 °C for 72 h. Aβ1--42 was incubated (A) alone, (B) with inhibitor peptide **20**, and (D) with the inactive peptide **43**. Peptides **20** and **43** incubated alone are shown in images (C,E), respectively. The scale bar shows 0.2 μm.](ao-2018-01522t_0004){#fig4}

![Visual investigation of the aggregation of Aβ~1--42~ peptide in the presence of tetrapeptides **20** and **43** by STEM. Aβ~1--42~ and tetrapeptides **20** and **43** were mixed for a concentration ratio of 1:5 (Aβ~1--42~/test peptides) and incubated at 37 °C for 72 h. Aβ~1--42~ was incubated, (A) alone, (B) with inhibitor peptide **20**, and (D) with the inactive peptide **43**. Peptides **20** and **43** incubated alone are shown in images (C,E), respectively. The scale bar shows 500 nm.](ao-2018-01522t_0005){#fig5}

However, when Aβ~1--42~ peptide was incubated with the inactive tetrapeptide **43**, small truncated aggregates were found in bunches ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}D, HRTEM and [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}D, STEM). Peptide **43**, when aged alone was also seen to form large clusters of amorphous aggregates ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}E, HRTEM and [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}E, STEM). Therefore, electron microscopy study further corroborates the inhibitory activity of the tetrapeptide **20**.

Cytotoxicity Study {#sec2.6}
------------------

Because the most active tetrapeptide **20** comprise all hydrophobic amino acid residues, whether it self-aggregates becomes worth-testing. Following a similar procedure as for the activity study, it was found that the inhibitor tetrapeptide **20** did not exert cytotoxic effects on the PC-12 cells at the highest tested concentration (20 μM). Cell samples treated with inhibitor peptide **20** showed viability as 97.7% (SD: 4.4).

Conclusions {#sec3}
===========

In view of the specific binding of peptide fragments for the parent peptide, amino acid scan was performed by means of independent amino acid replacement on the tetrapeptide fragment of Aβ~1--42~ and 43 new peptides were synthesized. Newly synthesized peptides consisted of both [l]{.smallcaps}- as well as [d]{.smallcaps}-isomers of the newly substituted amino acid residues. New tetrapeptide analogues were initially screened for their inhibition potential against the aggregating Aβ peptides by the MTT assay. ThT fluorescence experiments carried out for the best peptides well supported MTT results. CD spectral analysis and electron microscopy performed for one of the best inhibitor peptide further confirmed the observations. Total deterrence of Aβ aggregation along with noncytotoxic profiles makes the specific tetrapeptide **20** discovered herein as a promising lead for further development against AD.

Experimental Section {#sec4}
====================

General Chemistry {#sec4.1}
-----------------

All of the chemicals used for peptide synthesis were purchased from Sigma-Aldrich, Missouri, U.S.A,. and Chem-Impex International, Illinois, U.S.A., and used without further purification, unless otherwise stated. The solvents used were of analytical grade and used without further purification. Peptides were synthesized on a fully automated peptide synthesizer (AAPPTec Focus XC) by SPPS protocol using Fmoc chemistry on 0.1 mM scale. Wang resin, used as solid support, was preloaded with the C-terminus amino acid. ^1^H and ^13^C NMR spectra were recorded on a Bruker AVANCE III 400 MHz instrument using CD~3~OD as the solvent and tetramethylsilane as the internal standard. Proton and carbon chemical shifts are expressed in parts per million (ppm, δ scale) and were referenced to NMR solvent CD~3~OD, δ 3.31, 49.0 ppm. The following abbreviations were used to describe peak patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quadruplet, m = multiplet. Coupling constants (*J*) were reported in hertz unit (Hz). High-resolution mass spectroscopy (HRMS) spectra were obtained with MAXIS-Bruker using the electrospray ionization time-of-flight (ESI-TOF) method.

General Method for the Synthesis of Peptides {#sec4.2}
--------------------------------------------

After swelling the resin in DMF for 15 min in a sintered glass-bottom reaction vessel, Fmoc group was delinked from the C-terminus amino acid residue preloaded on the Wang resin, by using 20% piperidine in DMF for 15 min (2 × 10 mL). Afterward, the next residue followed by its in situ activation by treating with TBTU (3.0 equiv, 0.5 M in DMF) and DIEA (3.0 equiv, 1.0 M in DMF) was coupled with the resin bound C-terminus residue for 2.5 h at ambient temperature by mechanical shaking. HATU instead of TBTU was used as a coupling reagent to couple Aib. Kaiser's test was routinely utilized to monitor coupling reactions. Fmoc removal and subsequent coupling cycles with the next amino acid residues were repeated in succession to achieve the desired tetrapeptides. Tetrapeptides were first reacted with 20% piperdine for 15 min to remove N-terminus Fmoc groups. Peptides were then freed from resin and other protecting groups by magnetically stirring the resin-bound peptides in a cocktail of TFA/TIPS/H~2~O (95:3:2, 15 mL) for 2.5 h at ambient temperature. The solution was filtered and filtrate was concentrated to 0.5 mL. Addition of cold diethyl ether to the concentrate afforded the crude peptides. Crude peptides dissolved in a 1:1 mixture of H~2~O--CH~3~OH (v/v) were loaded on a preparative reversed-phase (RP)-HPLC (Shimadzu Prominence LC-8A model using a Phenomenex column, LC-18, 250 × 21.2 mm, 10 μm), operating at 215 nm. TFA (0.1%) in CH~3~CN (A) and 0.1% TFA in water (B) were used as mobile phase. A linear gradient of 10--60% of mobile phase A was run for 40 min at a flow rate of 21 mL/min. The desired fractions were pooled together and concentrated. Peptides were lyophilized by dissolving in 80% aqueous acetic acid. Purity check of the peptides was performed by analytical RP-HPLC (Shimadzu Prominence RP-HPLC system using a Phenomenex column, LC-18, 250 × 4.6 mm, 5 μm) by running a gradient run of 40 min, with a linear increase (10--90%) in mobile phase A. The flow rate was kept as 1.0 mL/min and operated at wavelength of 215 nm. The analysis showed the peptide purity in the range of 95--100%. The peptides were characterized and ascertained for identity by HRMS taken on a Maxis Bruker spectrometer and nuclear magnetic resonance spectroscopy using AVANCE III 400 Bruker (400 MHz).

Characterization Data of Synthesized Peptides {#sec4.3}
---------------------------------------------

### Val-Val-Ile-Ala (**1**) {#sec4.3.1}

^1^H NMR (400 MHz, CD~3~OD): δ 4.35--4.44 (m, 1H), 4.28 (br m, *J* = 4.27 Hz, 2H), 3.79 (br m, 1H), 2.15--2.26 (m, 1H), 1.99--2.10 (m, 1H), 1.80--1.91 (m, 1H), 1.51--1.65 (m, 1H), 1.37--1.43 (d, *J* = 7.24 Hz, 3H), 1.13--1.24 (m, 1H), 0.93--1.09 (m, 15H), 0.88 (t, *J* = 7.40 Hz, 3H); molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 17.17 min, 100%.

### [d]{.smallcaps}-Val-Val-Ile-Ala (**2**) {#sec4.3.2}

^1^H NMR (400 MHz, CD~3~OD): δ 4.39 (q, *J* = 7.28 Hz, 1H), 4.29 (d, *J* = 8.03 Hz, 1H), 4.24 (d, *J* = 7.03 Hz, 1H), 3.78 (d, *J* = 6.02 Hz, 1H), 2.22 (td, *J* = 6.90, 13.30 Hz, 1H), 2.12 (td, *J* = 6.87, 13.61 Hz, 1H), 1.81--1.90 (m, 1H), 1.62 (ddd, *J* = 3.14, 7.53, 13.43 Hz, 1H), 1.41 (d, *J* = 7.53 Hz, 3H), 1.13--1.25 (m, 1H), 1.08 (t, *J* = 6.90 Hz, 6H), 0.98 (d, *J* = 6.78 Hz, 9H), 0.88--0.95 (t, *J* = 7.36 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 172.2, 171.9, 168.6, 59.4, 58.4, 57.6, 57.5, 36.8, 30.4, 30.0, 24.4, 18.4, 17.6, 17.3, 16.4, 16.2, 15.8, 14.3; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 25.98 min, 97.8%.

### [d]{.smallcaps}-Ala-Val-Ile-Ala (**3**) {#sec4.3.3}

^1^H NMR (400 MHz, CD~3~OD): δ 4.34--4.44 (m, 1H), 4.23--4.31 (m, 2H), 4.05 (q, *J* = 6.86 Hz, 1H), 2.08--2.17 (m, 1H), 1.80--1.90 (m, 1H), 1.61 (ddd, *J* = 3.01, 7.65, 13.43 Hz, 1H), 1.55 (d, *J* = 7.03 Hz, 3H), 1.37--1.44 (m, 3H), 1.12--1.25 (m, 1H), 0.95--1.01 (m, 9H), 0.89--0.94 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 172.0, 171.8, 169.9, 59.0, 57.5, 53.4, 53.2, 36.8, 30.7, 24.4, 18.2, 17.1, 16.5, 16.2, 15.8, 14.2; molecular formula: C~17~H~32~N~4~O~5~; molecular weight: 372.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 373.2451 \[M + H^+^\]; found, 373.2451; HPLC: *t*~R~ = 21.85 min, 98.5%.

### [d]{.smallcaps}-Leu-Val-Ile-Ala (**4**) {#sec4.3.4}

^1^H NMR (400 MHz, CD~3~OD): δ 4.38 (q, *J* = 7.11 Hz, 1H), 4.29 (d, *J* = 8.28 Hz, 1H), 4.19--4.24 (m, 1H), 3.95--4.02 (br m, 1H), 2.06--2.17 (m, 1H), 1.81--1.89 (m, 1H), 1.65--1.79 (m, 3H), 1.56--1.64 (m, 1H), 1.38--1.44 (m, 3H), 1.12--1.24 (m, 1H), 0.94--1.07 (m, 15H), 0.91 (t, *J* = 6.78 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 172.2, 171.8, 169.6, 59.5, 57.6, 53.4, 51.7, 40.3, 36.8, 30.4, 24.4, 24.2, 21.4, 20.9, 18.3, 17.3, 16.1, 14.3, 14.2; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 28.59 min, 99.1%.

### Leu-Val-Ile-Ala (**5**) {#sec4.3.5}

^1^H NMR (400 MHz, CD~3~OD): δ 4.35--4.44 (m, 1H), 4.30 (br s, 2H), 3.92--4.04 (br d, 1H), 2.00--2.12 (m, 1H), 1.81--1.92 (m, 1H), 1.63--1.78 (m, 3H), 1.50--1.61 (m, 1H), 1.37--1.44 (d, *J* = 7.24 Hz, 3H), 1.12--1.24 (m, 1H), 0.93--1.05 (m, 15H), 0.89 (t, *J* = 7.15 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.0, 171.8, 171.7, 171.6, 59.2, 57.3, 57.2, 51.4, 40.5, 36.9, 30.5, 24.3, 23.9, 21.6, 20.9, 18.2, 17.8, 16.2, 15.9, 14.3; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 25.38 min, 96.3%.

### [d]{.smallcaps}-Ile-Val-Ile-Ala (**6**) {#sec4.3.6}

^1^H NMR (400 MHz, CD~3~OD): δ 4.34--4.43 (m, 1H), 4.27--4.31 (m, 1H), 4.22--4.26 (m, 1H), 3.86 (d, *J* = 5.52 Hz, 1H), 2.07--2.17 (m, 1H), 1.93--2.02 (m, 1H), 1.79--1.90 (m, 1H), 1.54--1.67 (m, 2H), 1.37--1.44 (m, 3H), 1.12--1.28 (m, 2H), 1.07 (d, *J* = 6.78 Hz, 3H), 0.95--1.03 (m, 12H), 0.87--0.94 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 172.2, 172.0, 171.9, 59.4, 57.7, 57.6, 52.5, 36.8, 36.6, 30.4, 24.5, 23.9, 19.0, 18.4, 17.4, 16.2, 15.8, 14.3, 14.2; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 23.74 min, 98.1%.

### Ile-Val-Ile-Ala (**7**) {#sec4.3.7}

^1^H NMR (400 MHz, CD~3~OD): δ 4.28 (q, *J* = 7.28 Hz, 1H), 4.09--4.20 (m, 2H), 3.71 (br d, *J* = 5.02 Hz, 1H), 1.88--1.99 (m, 1H), 1.78--1.87 (m, 1H), 1.69--1.78 (m, 1H), 1.39--1.54 (m, 2H), 1.25--1.34 (d, *J* = 7.28 Hz, 3H), 1.01--1.15 (m, 2H), 0.82--0.96 (m, 15H), 0.75--0.81 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 171.8, 171.7, 168.2, 59.3, 57.4, 57.3, 52.6, 36.8, 36.6, 30.5, 24.3, 23.9, 18.1, 17.8, 15.9, 14.1, 13.7, 10.2, 9.7; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 18.77 min, 99%.

### [d]{.smallcaps}-Pro-Val-Ile-Ala (**8**) {#sec4.3.8}

^1^H NMR (400 MHz, CD~3~OD): δ 4.34--4.42 (m, 2H), 4.27--4.33 (m, 2H), 3.41--3.49 (m, 1H), 3.35--3.41 (m, 1H), 2.46--2.55 (m, 1H), 2.03--2.17 (m, 4H), 1.80--1.90 (m, 1H), 1.60 (ddd, *J* = 3.26, 7.40, 13.43 Hz, 1H), 1.41 (dd, *J* = 6.02, 7.28 Hz, 3H), 1.12--1.24 (m, 1H), 0.97 (dd, *J* = 5.27, 6.78 Hz, 9H), 0.91 (dt, *J* = 3.01, 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.4, 173.1, 171.9, 171.8, 59.7, 59.3, 59.3, 52.5, 36.8, 30.7, 30.0, 24.4, 23.7, 18.2, 17.2, 16.2, 15.8, 14.3, 14.2; molecular formula: C~19~H~34~N~4~O~5~; molecular weight: 398.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 399.2607 \[M + H^+^\]; found, 399.2607; HPLC: *t*~R~ = 23.23 min, 98.9%.

### Pro-Val-Ile-Ala (**9**) {#sec4.3.9}

^1^H NMR (400 MHz, CD~3~OD): δ 4.34--4.41 (m, 2H), 4.29 (dd, *J* = 7.91, 16.19 Hz, 2H), 3.40--3.49 (m, 1H), 3.32--3.37 (m, 1H), 2.40--2.51 (m, 1H), 1.98--2.14 (m, 4H), 1.81--1.91 (m, 1H), 1.57 (ddd, *J* = 3.26, 7.65, 13.43 Hz, 1H), 1.39--1.43 (d, *J* = 7.28 Hz, 3H), 1.18 (ddd, *J* = 7.28, 9.29, 13.55 Hz, 1H), 0.93--1.03 (t, *J* = 7.36 Hz, 9H), 0.87--0.93 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 171.7, 171.7, 168.4, 59.6, 59.5, 57.3, 53.1, 37.0, 30.3, 29.8, 24.3, 23.5, 18.3, 17.6, 16.2, 15.9, 14.3, 14.3; molecular formula: C~19~H~34~N~4~O~5~; molecular weight: 398.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 399.2607 \[M + H^+^\]; found, 399.2606; HPLC: *t*~R~ = 16.63 min, 97.8%.

### Aib-Val-Ile-Ala (**10**) {#sec4.3.10}

^1^H NMR (400 MHz, CD~3~OD): δ 4.38 (q, *J* = 7.28 Hz, 1H), 4.28 (d, *J* = 8.03 Hz, 1H), 4.20 (d, *J* = 8.78 Hz, 1H), 2.05--2.16 (m, 1H), 1.81--1.91 (m, 1H), 1.64 (s, 3H), 1.61 (s, 3H), 1.57 (m, 1H), 1.41 (d, *J* = 7.28 Hz, 3H), 1.11--1.24 (m, 1H), 0.94--1.02 (m, 9H), 0.91 (t, *J* = 7.28 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 171.9, 171.7, 171.6, 59.8, 57.4, 56.9, 36.8, 30.2, 24.3, 22.7, 22.6, 18.3, 17.9, 16.2, 15.9, 14.3, 14.2; molecular formula: C~18~H~34~N~4~O~5~; molecular weight: 386.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 387.2607 \[M + H^+^\]; found, 387.2607; HPLC: *t*~R~ = 21.27 min, 99.2%.

### Nva-Val-Ile-Ala (**11**) {#sec4.3.11}

^1^H NMR (400 MHz, CD~3~OD): δ 4.37--4.44 (m, 1H), 4.29--4.37 (m, 2H), 3.98 (t, *J* = 6.40 Hz, 1H), 2.02--2.10 (m, 1H), 1.77--1.90 (m, 3H), 1.55 (ddd, *J* = 3.26, 7.53, 13.55 Hz, 1H), 1.34--1.46 (m, 5H), 1.17 (ddd, *J* = 7.28, 9.10, 13.74 Hz, 1H), 0.91--1.04 (m, 12H), 0.85--0.91 (dt, *J* = 7.36, 2.88 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 173.1, 171.8, 171.7, 59.3, 57.3, 57.3, 52.8, 36.9, 33.5, 30.4, 24.3, 18.2, 17.7, 17.7, 16.2, 15.9; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 18.25 min, 98.7%.

### Val-[d]{.smallcaps}-Val-Ile-Ala (**12**) {#sec4.3.12}

^1^H NMR (400 MHz, CD~3~OD): δ 4.36--4.45 (m, 1H), 4.29--4.34 (m, 1H), 4.21--4.27 (m, 1H), 3.74 (d, *J* = 6.27 Hz, 1H), 2.16--2.25 (m, 1H), 2.11 (dd, *J* = 6.78, 14.56 Hz, 1H), 1.95--2.00 (m, 1H), 1.49--1.58 (m, 1H), 1.41--1.46 (d, *J* = 7.32 Hz, 3H), 1.19--1.27 (m, 1H), 1.07 (d, *J* = 4.52 Hz, 3H), 1.09 (d, *J* = 4.52 Hz, 3H), 0.97--1.04 (m, 9H), 0.93 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.9, 173.8, 173.5, 173.3, 61.0, 60.9, 59.9, 59.3, 37.8, 37.8, 31.5, 31.4, 31.3, 25.7, 20.5, 19.9, 19.0, 18.9, 18.8; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2763; HPLC: *t*~R~ = 26.16 min, 96.8%.

### Val-[d]{.smallcaps}-Ala-Ile-Ala (**13**) {#sec4.3.13}

^1^H NMR (400 MHz, CD~3~OD): δ 4.50 (q, *J* = 7.28 Hz, 1H), 4.39 (q, *J* = 7.45 Hz, 1H), 4.29--4.33 (m, 1H), 3.65 (d, *J* = 6.53 Hz, 1H), 2.16--2.21 (m, 1H), 1.89--1.98 (m, 1H), 1.48--1.59 (m, 1H), 1.41 (d, *J* = 11.80 Hz, 3H), 1.42 (d, *J* = 12.05 Hz, 3H), 1.20--1.27 (m, 1H), 1.06 (d, *J* = 6.78 Hz, 6H), 0.99 (d, *J* = 6.78 Hz, 3H), 0.92 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.5, 173.3, 165.8, 62.5, 57.6, 53.7, 53.5, 53.2, 30.0, 24.3, 17.4, 16.7, 14.4, 10.0, 5.0; molecular formula: C~17~H~32~N~4~O~5~; molecular weight: 372.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 373.2451 \[M + H^+^\]; found, 373.2450; HPLC: *t*~R~ = 23.38 min, 96.8%.

### Val-[d]{.smallcaps}-Leu-Ile-Ala (**14**) {#sec4.3.14}

^1^H NMR (400 MHz, CD~3~OD): δ 4.37--4.43 (m, 1H), 4.25--4.33 (m, 1H), 4.14--4.22 (m, 1H), 3.57--3.60 (d, *J* = 6.0 Hz, 1H), 2.03--2.14 (m, 1H), 1.79--1.90 (m, 1H), 1.47--1.63 (m, 3H), 1.37--1.47 (m, 1H), 1.29--1.35 (t, *J* = 7.2 Hz, 3H), 1.06--1.16 (m, 1H), 0.92--1.00 (d, *J* = 6.8 Hz, 6H), 0.86--0.91 (m, 6H), 0.82 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.8, 173.3, 172.0, 168.6, 58.5, 57.8, 57.7, 53.7, 40.1, 40.0, 36.5, 36.5, 30.0, 24.6, 24.3, 21.7, 20.3, 20.3, 17.5, 16.6; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2915; HPLC: *t*~R~ = 29.76 min, 96.4%.

### Val-Leu-Ile-Ala (**15**) {#sec4.3.15}

^1^H NMR (400 MHz, CD~3~OD): δ 4.54 (t, *J* = 7.53 Hz, 1H), 4.35--4.45 (m, 1H), 4.22--4.29 (m, 1H), 3.70--3.74 (m, 1H), 2.16--2.27 (m, 1H), 1.85 (m, 1H), 1.64--1.73 (m, 1H), 1.52--1.64 (m, 3H), 1.40 (dd, *J* = 5.65, 7.15 Hz, 3H), 1.13--1.26 (m, 1H), 1.07 (d, *J* = 6.78, 3H), 1.03 (d, *J* = 7.03, 3H) 0.94--0.99 (m, 9H), 0.90 (dt, *J* = 2.51, 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.0, 172.5, 171.9, 171.7, 58.0, 57.5, 57.4, 51.3, 40.4, 36.9, 30.3, 24.4, 24.3, 21.9, 20.8, 17.5, 16.4, 16.2, 15.9, 14.3; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 25.07 min, 95.5%.

### Val-[d]{.smallcaps}-Ile-Ile-Ala (**16**) {#sec4.3.16}

^1^H NMR (400 MHz, CD~3~OD): δ 4.38--4.47 (m, 1H), 4.27--4.35 (m, 2H), 3.74--3.80 (m, 1H), 2.15--2.26 (m, 1H), 1.86--2.03 (m, 2H), 1.49--1.64 (m, 2H), 1.41--1.48 (m, 3H), 1.20--1.32 (m, 2H), 1.08 (dd, *J* = 3.26, 6.78 Hz, 6H), 0.97--1.03 (t, *J* = 5.56 Hz, 6H), 0.91--0.96 (dt, *J* = 7.32, 3.12 Hz, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 176.3, 174.1, 173.4, 170.3, 59.9, 59.7, 59.4, 54.9, 37.9, 37.7, 37.4, 37.2, 31.5, 27.4, 26.0, 25.7, 19.0, 18.9, 18.0, 17.6; molecular formula: C~20~H~38~N~4~O~5~; Molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2920; HPLC: *t*~R~ = 29.56 min, 99.3%.

### Val-Ile-Ile-Ala (**17**) {#sec4.3.17}

^1^H NMR (400 MHz, CD~3~OD): δ 4.35--4.45 (m, 1H), 4.24--4.33 (m, 2H), 3.77 (br s, 1H), 2.13--2.26 (m, 1H), 1.76--1.91 (m, 2H), 1.51--1.69 (m, 2H), 1.36--1.44 (d, *J* = 7.28 Hz, 3H), 1.11--1.26 (m, 2H), 1.03 (d, *J* = 7.03 Hz, 3H), 1.05 (d, *J* = 6.78 Hz, 3H), 0.87--0.99 (m, 12H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.3, 171.8, 171.7, 168.0, 58.0, 57.3, 53.3, 36.6, 36.5, 30.4, 24.7, 24.4, 17.5, 16.4, 16.3, 15.9, 14.3, 9.7; molecular formula: C~20~H~38~N~4~O~5~; molecular weight: 414.2842; HRMS (ESI-TOF): calcd for *m*/*z*, 415.2920 \[M + H^+^\]; found, 415.2915; HPLC: *t*~R~ = 18.19 min, 96.1%.

### Val-[d]{.smallcaps}-Pro-Ile-Ala (**18**) {#sec4.3.18}

^1^H NMR (400 MHz, CD~3~OD): δ 4.57 (dd, *J* = 3.76, 8.53 Hz, 1H), 4.39--4.46 (m, 1H), 4.31--4.37 (m, 1H), 4.04 (d, *J* = 6.53 Hz, 1H), 3.76--3.83 (m, 1H), 3.63--3.73 (m, 1H), 2.21--2.34 (m, 2H), 2.04--2.20 (m, 1H), 1.95--2.03 (m, 2H), 1.52 (ddd, *J* = 3.39, 7.53, 13.43 Hz, 2H), 1.42--1.46 (t, *J* = 7.24 Hz, 3H), 1.18--1.27 (m, 1H), 1.08--1.13 (m, 6H), 0.99 (d, *J* = 6.78 Hz, 3H), 0.91--0.95 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.7, 173.3, 171.8, 167.5, 60.3, 57.7, 56.9, 53.5, 36.5, 29.5, 29.4, 24.3, 24.1, 19.1, 17.6, 16.2, 16.1, 15.8, 14.5; molecular formula: C~19~H~34~N~4~O~5~; molecular weight: 398.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 399.2607 \[M + H^+^\]; found, 399.2607; HPLC: *t*~R~ = 21.03 min, 99.2%.

### Val-Pro-Ile-Ala (**19**) {#sec4.3.19}

^1^H NMR (400 MHz, CD~3~OD): δ 4.57 (dd, *J* = 5.40, 8.41 Hz, 1H), 4.36--4.43 (m, 1H), 4.21--4.27 (m, 1H), 4.07 (d, *J* = 5.27 Hz, 1H), 3.74 (td, *J* = 6.34, 9.66 Hz, 1H), 3.59--3.67 (m, 1H), 2.20--2.35 (m, 2H), 2.06--2.15 (m, 1H), 1.93--2.02 (m, 2H), 1.80--1.90 (m, 1H), 1.56--1.67 (m, 1H), 1.37--1.43 (m, 3H), 1.18--1.31 (m, 1H), 1.15 (d, *J* = 7.03 Hz, 3H), 1.06 (d, *J* = 6.78 Hz, 3H), 0.96--1.02 (d, *J* = 6.84 Hz, 3H), 0.88--0.94 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.5, 173.2, 172.5, 172.0, 60.2, 57.8, 57.7, 52.6, 37.1, 32.0, 29.5, 29.0, 24.7, 24.3, 17.9, 17.7, 16.2, 15.9, 15.9; molecular formula: C~19~H~34~N~4~O~5~; molecular weight: 398.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 399.2607 \[M + H^+^\]; found, 399.2614; HPLC: *t*~R~ = 20.77 min, 97.5%.

### Val-Aib-Ile-Ala (**20**) {#sec4.3.20}

^1^H NMR (400 MHz, CD~3~OD): δ 4.36--4.43 (m, 1H), 4.29--4.34 (m, 1H), 3.68 (d, *J* = 5.77 Hz, 1H), 2.23 (qd, *J* = 6.81, 13.21 Hz, 1H), 1.89 (tdd, *J* = 3.45, 6.81, 13.14 Hz, 1H), 1.59--1.63 (m, 1H), 1.55--1.58 (s, 3H), 1.52 (s, 3H), 1.38--1.45 (m, 3H), 1.15--1.26 (m, 1H), 1.07 (d, *J* = 10.04 Hz, 3H), 1.09 (d, *J* = 10.29 Hz, 3H), 0.99 (d, *J* = 6.78 Hz, 3H), 0.92 (dt, *J* = 2.76, 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 176.0, 175.9, 174.6, 173.5, 59.8, 59.1, 59.0, 54.0, 38.6, 31.5, 25.8, 25.0, 19.0, 17.9, 17.5, 17.2, 15.8, 15.7; molecular formula: C~18~H~34~N~4~O~5~; molecular weight: 386.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 387.2607 \[M + H^+^\]; found, 387.2607; HPLC: *t*~R~ = 22.93 min, 98.5%.

### Val-[d]{.smallcaps}-Phe-Ile-Ala (**21**) {#sec4.3.21}

^1^H NMR (400 MHz, CD~3~OD): δ 7.26--7.33 (m, 4H), 7.19--7.26 (m, 1H), 4.82 (dd, *J* = 6.78, 9.29 Hz, 1H), 4.35--4.43 (m, 1H), 4.23 (d, *J* = 6.78 Hz, 1H), 3.65 (d, *J* = 5.77 Hz, 1H), 3.17 (dd, *J* = 6.65, 13.68 Hz, 1H), 2.87--2.98 (dd, *J* = 9.32, 4.28 Hz, 1H), 1.94--2.02 (m, 1H), 1.84--1.86 (m, 1H), 1.43 (t, *J* = 7.20 Hz, 3H), 1.33--1.40 (m, 1H), 1.00--1.10 (m, 1H), 0.81--0.90 (m, 9H), 0.75--0.80 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.7, 172.0, 171.9, 168.4, 136.4, 128.9, 128.3, 126.6, 58.4, 57.8, 57.7, 54.8, 37.3, 36.6, 29.9, 24.2, 17.3, 16.2, 16.1, 15.8, 14.3; molecular formula: C~23~H~36~N~4~O~5~; molecular weight: 448.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 449.2764 \[M + H^+^\]; found, 449.2764; HPLC: *t*~R~ = 22.72 min, 98.9%.

### Val-Phe-Ile-Ala (**22**) {#sec4.3.22}

^1^H NMR (400 MHz, CD~3~OD): δ 7.24--7.30 (m, 4H), 7.18--7.24 (m, 1H), 4.78 (ddd, *J* = 3.01, 6.96, 8.09 Hz, 1H), 4.32 (dq, *J* = 3.39, 7.32 Hz, 1H), 4.21 (dd, *J* = 4.52, 8.28 Hz, 1H), 3.71 (d, *J* = 5.27 Hz, 1H), 3.08--3.16 (m, 1H), 2.93--3.03 (m, 1H), 2.16--2.27 (m, 1H), 1.75--1.85 (m, 1H), 1.48--1.61 (m, 1H), 1.37--1.44 (dd, *J* = 5.68, 1.6 Hz, 3H), 1.16 (ddd, *J* = 7.28, 9.03, 13.80 Hz, 1H), 1.02 (d, *J* = 7.03 Hz, 3H), 1.06 (d, *J* = 7.03 Hz, 3H), 0.95 (dd, *J* = 0.88, 6.90 Hz, 3H), 0.88 (dt, *J* = 2.26, 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 175.9, 174.6, 173.0, 172.9, 137.9, 130.3, 129.5, 127.9, 59.5, 58.8, 58.7, 56.2, 38.7, 38.4, 31.7, 25.8, 18.9, 17.7, 17.6, 17.2, 15.6; molecular formula: C~23~H~36~N~4~O~5~; molecular weight: 448.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 449.2764 \[M + H^+^\]; found, 449.2764; HPLC: *t*~R~ = 23.87 min, 98.6%.

### Val-Nva-Ile-Ala (**23**) {#sec4.3.23}

^1^H NMR (400 MHz, CD~3~OD): δ 4.47 (dd, *J* = 6.40, 8.16 Hz, 1H), 4.35--4.43 (m, 1H), 4.24--4.30 (m, 1H), 3.74 (d, *J* = 5.52 Hz, 1H), 2.21 (m, 1H), 1.81--1.91 (m, 1H), 1.72--1.80 (m, 1H), 1.63--1.71 (m, 1H), 1.52--1.62 (m, 1H), 1.43--1.47 (m, 1H), 1.40 (d, *J* = 7.32 Hz, 3H), 1.33--1.38 (m, 1H), 1.19 (ddd, *J* = 7.28, 9.22, 13.61 Hz, 1H), 1.05 (d, *J* = 6.78 Hz, 3H), 1.03 (d, *J* = 7.03 Hz, 3H), 0.92--1.00 (m, 6H), 0.89 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.4, 172.3, 171.8, 168.1, 58.1, 57.5, 57.4, 52.5, 36.9, 33.8, 30.2, 24.3, 18.7, 17.5, 16.4, 16.2, 15.9, 14.3, 14.2; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 18.08 min, 98.1%.

### Aib-Aib-Ile-Ala (**24**) {#sec4.3.24}

^1^H NMR (400 MHz, CDCl~3~): δ 4.28--4.37 (m, 2H), 1.80--1.87 (tdd, *J* = 3.36, 6.40, 9.72 Hz, 1H), 1.62 (s, 3H), 1.56 (s, 3H), 1.51--1.54 (m, 1H), 1.46--1.50 (d, *J* = 6.78 Hz, 6H), 1.39--1.42 (d, *J* = 7.28 Hz, 3H), 1.09--1.16 (m, 1H), 0.96 (d, *J* = 6.78 Hz, 3H), 0.86--0.92 (m, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 178.3, 176.2, 176.0, 175.9, 60.9, 56.5, 52.2, 52.1, 42.9, 41.4, 41.1, 33.2, 28.5, 28.2, 27.1, 26.6, 26.3, 23.0, 20.0; molecular formula: C~17~H~32~N~4~O~5~; molecular weight: 372.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 373.2451 \[M + H^+^\]; found, 373.2459; HPLC: *t*~R~ = 7.77 min, 100%.

### Pro-Pro-Ile-Ala (**25**) {#sec4.3.25}

^1^H NMR (400 MHz, CD~3~OD): δ 4.51--4.62 (m, 2H), 4.34--4.44 (m, 1H), 4.21--4.27 (m, 1H), 3.64--3.74 (m, 1H), 3.60 (td, *J* = 6.74, 9.85 Hz, 1H), 3.35--3.48 (m, 2H), 2.47--2.58 (m, 1H), 2.21--2.32 (m, 1H), 2.06--2.17 (m, 4H), 1.96--2.05 (m, 2H) 1.79--1.90 (m, 1H), 1.61 (ddd, *J* = 3.14, 7.59, 13.36 Hz, 1H), 1.39--1.44 (m, 3H), 1.21 (ddd, *J* = 7.40, 9.41, 13.55 Hz, 1H), 0.99 (d, *J* = 6.78 Hz, 3H), 0.87--0.94 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 172.4, 172.3, 172.0, 171.9, 60.3, 60.2, 59.0, 57.8, 37.1, 37.0, 32.0, 29.1, 28.4, 28.2, 24.6, 24.4, 23.9, 23.7, 19.1; molecular formula: C~19~H~32~N~4~O~5~; molecular weight: 396.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 397.2451 \[M + H^+^\]; found, 397.2451; HPLC: *t*~R~ = 14.71 min, 95.4%.

### Val-Val-[d]{.smallcaps}-Ile-Ala (**26**) {#sec4.3.26}

^1^H NMR (400 MHz, CD~3~OD): δ 4.37--4.45 (m, 1H), 4.28--4.35 (m, 1H), 4.19--4.25 (m, 1H), 3.69--3.76 (m, 1H), 2.14--2.22 (m, 1H), 2.04--2.12 (m, 1H), 1.93--2.02 (m, 1H), 1.49--1.61 (m, 1H), 1.40--1.45 (m, 3H), 1.17--1.25 (m, 1H), 1.02 (d, *J* = 6.78 Hz, 6H), 1.04 (d, *J* = 7.03 Hz, 6H), 0.89--0.98 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.5, 173.2, 172.0, 171.9, 59.9, 59.8, 58.1, 57.9, 36.5, 30.3, 30.0, 29.9, 24.3, 18.3, 17.7, 17.6, 17.6, 16.5, 16.4; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 27.60 min, 96.0%.

### Val-Val-[d]{.smallcaps}-Ala-Ala (**27**) {#sec4.3.27}

^1^H NMR (400 MHz, CD~3~OD): δ 4.36--4.48 (m, 2H), 4.04--4.12 (m, 1H), 3.70--3.76 (m, 1H), 2.13--2.24 (m, 1H), 2.06 (m, 1H), 1.36--1.45 (m, 6H), 0.97--1.10 (m, 12H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.3, 173.0, 171.6, 168.8, 60.0, 58.1, 53.5, 52.5, 30.3, 29.9, 18.0, 17.8, 17.6, 16.6, 16.5, 16.4; molecular formula: C~16~H~30~N~4~O~5~; molecular weight: 358.2216; HRMS (ESI-TOF): calculated for m/z 359.2294 \[M + H^+^\]; found, 359.2294; HPLC: *t*~R~ = 12.42 min, 96.6%.

### Val-Val-[d]{.smallcaps}-Leu-Ala (**28**) {#sec4.3.28}

^1^H NMR (400 MHz, CD~3~OD): δ 4.34--4.49 (m, 2H), 4.04--4.11 (m, 1H), 3.69--3.74 (d, *J* = 7.52 Hz, 1H), 2.11--2.22 (m, 1H), 2.02--2.10 (m, 1H), 1.59--1.73 (m, 3H), 1.38--1.44 (d, *J* = 7.28 Hz, 3H), 0.98--1.08 (m, 12H), 0.96 (d, *J* = 5.77 Hz, 3H), 0.91 (d, *J* = 5.77 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 172.1, 172.0, 168.8, 168.7, 60.4, 58.1, 53.4, 53.2, 46.9, 40.1, 30.3, 29.8, 24.4, 22.1, 19.8, 18.1, 17.9, 17.6, 16.6, 16.3; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 23.28 min, 95.6%.

### Val-Val-Leu-Ala (**29**) {#sec4.3.29}

^1^H NMR (400 MHz, CD~3~OD): δ 4.47--4.54 (m, 1H), 4.35--4.43 (m, 1H), 4.20--4.26 (m, 1H), 3.79 (d, *J* = 5.77 Hz, 1H), 2.16--2.25 (m, 1H), 2.04--2.11 (m, 1H), 1.66--1.77 (m, 1H), 1.58--1.64 (m, 2H), 1.37--1.43 (m, 3H), 0.97--1.07 (m, 12H), 0.94--0.97 (m, 3H), 0.89--0.93 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 172.9, 172.7, 171.7, 59.2, 58.0, 53.5, 51.3, 40.6, 40.5, 30.3, 24.2, 22.1, 22.0, 20.6, 20.5, 19.1, 18.3, 18.2; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 16.68 min, 96.7%.

### Val-Val-[d]{.smallcaps}-Val-Ala (**30**) {#sec4.3.30}

^1^H NMR (400 MHz, CD~3~OD): δ 4.37--4.45 (m, 1H), 4.25--4.30 (m, 1H), 4.23 (d, *J* = 6.78 Hz, 1H), 3.73 (d, *J* = 5.77 Hz, 1H), 2.14--2.30 (m, 2H), 2.04--2.13 (m, 1H), 1.38--1.46 (d, *J* = 7.24 Hz, 3H), 1.00--1.07 (m, 12H), 0.96--1.01 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 172.1, 171.8, 168.6, 168.4, 59.9, 59.8, 58.6, 58.6, 30.3, 30.1, 30.0, 29.9, 29.8, 18.5, 18.3, 17.7; molecular formula: C~18~H~34~N~4~O~5~; molecular weight: 386.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 387.2607 \[M + H^+^\]; found, 387.2607; HPLC: *t*~R~ = 24.51 min, 99.2%.

### Val-Val-Val-Ala (**31**) {#sec4.3.31}

^1^H NMR (400 MHz, CD~3~OD): δ 4.36--4.44 (m, 1H), 4.21--4.32 (m, 2H), 3.80 (br s, 1H), 2.21 (dd, *J* = 6.78, 13.05 Hz, 1H), 2.03--2.14 (m, 2H), 1.38--1.43 (m, 3H), 0.93--1.08 (m, 18H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.4, 173.2, 171.8, 171.6, 59.3, 58.4, 58.3, 52.6, 30.8, 30.4, 30.3, 19.1, 18.2, 18.0, 17.7, 17.5, 17.4, 16.4; molecular formula: C~18~H~34~N~4~O~5~; molecular weight: 386.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 387.2607 \[M + H^+^\]; found, 387.2606; HPLC: *t*~R~ = 15.09 min, 96.9%.

### Val-Val-[d]{.smallcaps}-Pro-Ala (**32**) {#sec4.3.32}

^1^H NMR (400 MHz, CD~3~OD): δ 4.48--4.49 (m, 1H), 4.36--4.45 (m, 2H), 4.01 (m, 1H), 3.66--3.77 (m, 2H), 2.07--2.19 (m, 5H), 1.35--1.46 (m, 4H), 1.00--1.07 (m, 12H); ^13^C NMR (100 MHz, CD~3~OD): δ 159.7, 159.3, 158.8, 158.4, 61.7, 59.6, 58.8, 54.9, 31.8, 31.7, 31.2, 31.0, 30.8, 25.2, 19.3, 19.1, 18.8, 18.1; molecular formula: C~18~H~32~N~4~O~5~; molecular weight: 384.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 385.2451 \[M + H^+^\]; found, 385.2450; HPLC: *t*~R~ = 14.12 min, 97.8%.

### Val-Val-Pro-Ala (**33**) {#sec4.3.33}

^1^H NMR (400 MHz, CD~3~OD): δ 4.43--4.52 (m, 2H), 4.34--4.41 (m, 1H), 3.92--4.01 (m, 1H), 3.76 (d, *J* = 4.27 Hz, 1H), 3.67--3.73 (m, 1H), 2.06--2.26 (m, 4H), 1.95--2.04 (m, 2H), 1.38--1.45 (d, *J* = 7.40 Hz, 3H), 0.99--1.09 (m, 12H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.7, 172.6, 170.7, 168.3, 59.9, 59.8, 58.0, 52.6, 30.3, 30.0, 29.1, 24.5, 19.1, 18.1, 17.5, 17.3, 16.4, 16.0; molecular formula: C~18~H~32~N~4~O~5~; molecular weight: 384.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 385.2451 \[M + H^+^\]; found, 385.2441; HPLC: *t*~R~ = 8.87 min, 95.9%.

### Val-Val-Aib-Ala (**34**) {#sec4.3.34}

^1^H NMR (400 MHz, CD~3~OD): δ 4.33--4.43 (m, 1H), 4.10 (d, *J* = 7.53 Hz, 1H), 3.73 (d, *J* = 6.53 Hz, 1H), 2.13--2.23 (m, 1H), 2.02--2.10 (m, 1H), 1.51 (s, 3H), 1.47 (s, 3H) 1.39 (d, *J* = 7.28 Hz, 3H), 0.98--1.10 (m, 12H); ^13^C NMR (100 MHz, CD~3~OD): δ 175.2, 173.6, 171.2, 168.7, 59.7, 58.2, 56.5, 54.3 30.3, 30.2, 25.2, 22.6, 18.1, 17.7, 16.7, 16.3; molecular formula: C~17~H~32~N~4~O~5~; molecular weight: 372.2373; HRMS (ESI-TOF): calcd for *m*/*z*, 373.2451 \[M + H^+^\]; found, 373.2450; HPLC: *t*~R~ = 12.99 min, 100%.

### Val-Val-[d]{.smallcaps}-Phe-Ala (**35**) {#sec4.3.35}

^1^H NMR (400 MHz, CD~3~OD): δ 7.24--7.29 (m, 4H), 7.19 (qd, *J* = 4.27, 8.53 Hz, 1H), 4.70--4.76 (m, 1H), 4.39--4.46 (m, 1H), 3.96--4.00 (m, 1H), 3.68--3.72 (m, 1H), 3.27--3.33 (m, 1H), 2.85 (dd, *J* = 10.54, 14.05 Hz, 1H), 2.15 (qd, *J* = 6.87, 13.52 Hz, 1H), 1.81 (dd, *J* = 6.78, 14.56 Hz, 1H), 1.37--1.40 (d, *J* = 7.28 Hz, 3H), 0.99--1.05 (t, *J* = 6.52 Hz, 6H), 0.80 (d, *J* = 6.78 Hz, 3H), 0.54--0.60 (d, *J* = 6.76 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.6, 173.3, 171.8, 171.7, 137.1, 128.8, 128.1, 126.4, 60.2, 60.1, 58.0, 54.6, 37.2, 30.3, 29.7, 29.6, 17.8, 17.7, 17.6, 17.5; molecular formula: C~22~H~34~N~4~O~5~; molecular weight: 434.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 435.2607 \[M + H^+^\]; found, 435.2607; HPLC: *t*~R~ = 17.49 min, 97.4%.

### Val-Val-Phe-Ala (**36**) {#sec4.3.36}

^1^H NMR (400 MHz, CD~3~OD): δ 7.21--7.30 (m, 4H), 7.14--7.20 (m, 1H), 4.72 (dd, *J* = 5.27, 9.29 Hz, 1H), 4.36--4.42 (m, 1H), 4.20--4.26 (m, 1H), 3.71--3.76 (m, 1H), 3.16 (dd, *J* = 5.02, 14.05 Hz, 1H), 2.93 (dd, *J* = 9.29, 14.05 Hz, 1H), 2.18--2.24 (m, 1H), 2.04--2.16 (m, 1H) 1.39--1.42 (m, 3H), 1.00--1.07 (m, 6H), 0.92--0.94 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 171.5, 171.4, 168.4, 168.2, 136.8, 136.7, 129.0, 128.1, 126.4, 59.0, 58.1, 54.2, 53.5, 37.5, 30.7, 30.6, 30.5, 30.3, 19.1, 18.2, 16.2; molecular formula: C~22~H~34~N~4~O~5~; molecular weight: 434.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 435.2607 \[M + H^+^\]; found, 435.2607; HPLC: *t*~R~ = 25.75 min, 98.4%.

### Val-Val-Nva-Ala (**37**) {#sec4.3.37}

^1^H NMR (400 MHz, CD~3~OD): δ 4.35--4.47 (m, 2H), 4.24--4.31 (m, 1H), 3.79 (d, *J* = 5.77 Hz, 1H), 2.14--2.25 (m, 1H), 2.07 (td, *J* = 6.78, 8.03 Hz, 1H), 1.73--1.85 (m, 1H), 1.64 (dtd, *J* = 5.02, 9.14, 13.83 Hz, 1H), 1.42--1.47 (m, 1H), 1.38--1.41 (d, *J* = 7.28 Hz, 3H), 1.34--1.38 (m, 1H), 0.96--1.09 (m, 12H), 0.89--0.94 (t, *J* = 7.40 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 172.5, 172.4, 171.7, 59.2, 58.0, 53.4, 52.6, 34.0, 30.4, 30.3, 19.0, 18.5, 18.2, 17.6, 17.4, 16.5, 16.2; molecular formula: C~18~H~34~N~4~O~5~; molecular weight: 386.2529; HRMS (ESI-TOF): calcd for *m*/*z*, 387.2607 \[M + H^+^\]; found, 387.2603; HPLC: *t*~R~ = 14.59 min, 99.3%.

### Val-Val-Nle-Ala (**38**) {#sec4.3.38}

1H NMR (400 MHz, CD~3~OD): δ 4.35--4.46 (m, 2H), 4.24--4.32 (m, 1H), 3.79 (d, *J* = 5.77 Hz, 1H), 2.15--2.25 (m, 1H), 2.02--2.12 (m, 1H), 1.81 (m, 1H), 1.60--1.71 (m, 1H), 1.41 (d, *J* = 7.28 Hz, 3H), 1.31--1.37 (m, 4H), 1.01--1.05 (dd, *J* = 7.0, 1.96 Hz, 6H), 0.96--1.00 (t, *J* = 6.28 Hz, 6H), 0.87--0.94 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 172.5, 172.4, 171.6, 59.1, 58.0, 53.5, 52.6, 31.7, 30.4, 30.3, 27.5, 22.0, 19.0, 18.2, 17.6, 17.5, 16.5, 16.2; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2764; HPLC: *t*~R~ = 18.53 min, 97.4%.

### Val-Val-Ile-[d]{.smallcaps}-Ala (**39**) {#sec4.3.39}

^1^H NMR (400 MHz, CD~3~OD): δ 4.37--4.45 (m, 1H), 4.28--4.35 (m, 2H), 3.83 (d, *J* = 5.52 Hz, 1H), 2.16--2.26 (m, 1H), 2.03--2.10 (m, 1H), 1.79--1.89 (m, 1H), 1.49--1.61 (m, 1H), 1.41 (t, *J* = 7.03 Hz, 3H), 1.12--1.22 (m, 1H), 1.05 (t, *J* = 6.40 Hz, 6H), 1.00 (dd, *J* = 1.63, 6.65 Hz, 3H), 0.96 (d, *J* = 6.53 Hz, 3H), 0.93 (dd, *J* = 1.51, 6.78 Hz, 3H), 0.87 (t, *J* = 7.53 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.0, 171.8, 171.7, 171.5, 59.3, 58.0, 57.4, 52.6, 36.8, 36.7, 30.5, 30.4, 24.4, 18.2, 18.1, 17.9, 17.4, 16.7, 16.6; molecular formula: C~19~H~36~N~4~O~5~; molecular weight: 400.2686; HRMS (ESI-TOF): calcd for *m*/*z*, 401.2764 \[M + H^+^\]; found, 401.2757; HPLC: *t*~R~ = 20.19 min, 97.0%.

### Val-Val-Ile-Val (**40**) {#sec4.3.40}

^1^H NMR (400 MHz, CDCl~3~): δ 4.34--4.39 (m, 1H), 4.28--4.33 (m, 1H), 4.24 (dd, *J* = 5.77, 8.28 Hz, 1H), 3.77--3.84 (br s, 1H), 2.15 (spt, *J* = 6.48 Hz, 2H), 2.0--2.08 (m, 1H), 1.83--1.88 (m, 1H), 1.51 (m, 1H), 1.15--1.23 (m, 1H), 0.93--1.03 (m, 18H), 0.92 (d, *J* = 6.78 Hz, 3H), 0.85--0.89 (t, *J* = 7.48 Hz, 3H); ^13^C NMR (100 MHz, CDCl~3~): δ 177.9, 175.9, 173.9, 171.9, 54.3, 53.4, 53.0, 52.1, 31.9, 31.6, 31.4, 30.2, 29.7, 29.6, 29.5, 29.4, 29.2, 29.0, 24.7, 22.7; molecular formula: C~21~H~40~N~4~O~5~; molecular weight: 428.2999; HRMS (ESI-TOF): calcd for *m*/*z*, 429.3077 \[M + H^+^\]; found, 429.3077; HPLC: *t*~R~ = 22.03 min, 100%.

### Val-Val-Ile-Leu (**41**) {#sec4.3.41}

^1^H NMR (400 MHz, CD~3~OD): δ 4.33--4.44 (m, 1H), 4.13--4.25 (m, 2H), 3.72 (d, *J* = 5.52 Hz, 1H), 2.10 (qd, *J* = 6.73, 13.18 Hz, 1H), 1.89--1.95 (m, 1H), 1.74 (td, *J* = 6.27, 9.29 Hz, 1H), 1.51--1.62 (m, 3H), 1.39--1.50 (m, 1H), 1.00--1.13 (m, 1H), 0.94 (t, *J* = 6.40 Hz, 6H), 0.81--0.91 (m, 12H), 0.74--0.80 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 174.6, 173.2, 172.3, 172.2, 59.2, 58.0, 57.3, 57.2, 40.1, 39.8, 30.6, 30.4, 24.4, 24.2, 22.0, 21.9, 20.2, 20.1, 18.1, 17.8, 17.4; molecular formula: C~22~H~42~N~4~O~5~; molecular weight: 442.3155; HRMS (ESI-TOF): calcd for *m*/*z*, 443.3233 \[M + H^+^\]; found, 443.3230; HPLC: *t*~R~ = 25.54 min, 100%.

### Val-Val-Ile-Ile (**42**) {#sec4.3.42}

^1^H NMR (400 MHz, CD~3~OD): δ 4.36--4.42 (m, 2H), 4.33 (d, *J* = 8.78 Hz, 1H), 3.84 (d, *J* = 5.52 Hz, 1H), 2.15--2.26 (m, 1H), 2.01--2.08 (m, 1H), 1.79--1.96 (m, 2H), 1.54 (ddt, *J* = 3.76, 7.53, 13.55 Hz, 2H), 1.13--1.28 (m, 2H), 1.05 (t, *J* = 6.65 Hz, 6H), 1.00 (d, *J* = 6.53 Hz, 3H), 0.91--0.97 (m, 12H), 0.84--0.89 (m, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.4, 172.3, 171.6, 168.1, 59.2, 58.0, 57.3, 56.9, 36.8, 36.7, 30.6, 30.4, 24.7, 24.5, 18.2, 17.8, 17.4, 16.6, 16.5, 14.6, 14.3, 10.2; molecular formula: C~22~H~42~N~4~O~5~; molecular weight: 442.3155; HRMS (ESI-TOF): calcd for *m*/*z*, 443.3233 \[M + H^+^\]; found, 443.3233; HPLC: *t*~R~ = 16.71 min, 96.7%.

### Val-Val-Ile-[d]{.smallcaps}-Phe (**43**) {#sec4.3.43}

^1^H NMR (400 MHz, CD~3~OD): δ 7.07--7.17 (m, 5H), 4.62 (dd, *J* = 4.52, 10.04 Hz, 1H), 4.16 (dd, *J* = 3.26, 8.03 Hz, 2H), 3.67 (d, *J* = 5.27 Hz, 1H), 3.17 (dd, *J* = 4.39, 14.18 Hz, 1H), 2.83 (dd, *J* = 10.29, 14.05 Hz, 1H), 2.04--2.11 (m, 1H), 1.83--1.95 (m, 2H), 1.55--1.57 (m, 1H), 1.13--1.26 (m, 1H), 0.91 (t, *J* = 7.15 Hz, 6H), 0.86 (d, *J* = 6.78 Hz, 3H), 0.80 (d, *J* = 6.53 Hz, 3H), 0.62 (t, *J* = 7.40 Hz, 3H), 0.49 (d, *J* = 6.78 Hz, 3H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 172.1, 172.0, 171.4, 128.7, 128.1, 126.5, 126.4, 59.2, 58.0, 57.2, 56.9, 37.0, 36.9, 36.7, 30.5, 30.4, 24.4, 19.1, 18.3, 17.9, 17.4, 17.6; molecular formula: C~25~H~40~N~4~O~5~; molecular weight: 476.2999; HRMS (ESI-TOF): calcd for *m*/*z*, 477.3077 \[M + H^+^\]; found, 477.3077; HPLC: *t*~R~ = 36.92 min, 99.9%.

### Val-Val-Ile-Phe (**44**) {#sec4.3.44}

^1^H NMR (400 MHz, CD~3~OD): δ 7.18--7.26 (m, 5H), 4.70 (dd, *J* = 5.02, 8.78 Hz, 1H), 4.23--4.34 (m, 2H), 3.81 (d, *J* = 5.77 Hz, 1H), 3.17--3.24 (dd, *J* = 14.08, 5.04 Hz, 1H), 3.00 (dd, *J* = 8.78, 14.05 Hz, 1H), 2.13--2.23 (m, 1H), 1.92--2.01 (m, 1H), 1.75--1.85 (m, 1H), 1.51 (ddd, *J* = 3.26, 7.53, 13.55 Hz, 1H), 1.09--1.19 (m, 1H), 1.03 (t, *J* = 6.27 Hz, 6H), 0.93--0.95 (d, *J* = 6.68 Hz, 3H), 0.89--0.95 (d, *J* = 6.76 Hz, 3H), 0.79--0.88 (m, 6H); ^13^C NMR (100 MHz, CD~3~OD): δ 173.2, 172.1, 172.0, 171.4, 128.7, 128.1, 126.5, 126.4, 59.2, 58.0, 57.2, 56.9, 37.0, 36.9, 36.7, 30.5, 30.4, 24.4, 19.1, 18.3, 17.9, 17.4, 16.6; molecular formula: C~25~H~40~N~4~O~5~; molecular weight: 476.2999; HRMS (ESI-TOF): calcd for *m*/*z*, 477.3077 \[M + H^+^\]; found, 477.3077; HPLC: *t*~R~ = 19.49 min, 98.7%.

MTT Cell Viability Assay {#sec4.4}
------------------------

\[3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium\]bromide (MTT) reduction in the mitochondria of living cells results into purple-colored formazan crystals that can be measured spectrophotometrically. The observed optical density (OD) is directly proportional to the number of live cells, hence, of utmost importance in the evaluation of cellular viability in drug screening and neuronal cytotoxicity.^[@ref43]^ PC-12 cells were purchased from National Center for Cell Science (NCCS), Pune, India. Aβ peptides were purchased from AnaSpec Inc., USA. Horse serum was purchased from HiMedia Laboratories, India. 96-well, flat-bottom microtiter plates (Costar), Corning tissue-culture treated dishes, F-12K growth media, sodium bicarbonate, MTT, penicillin/streptomycin and fetal bovine serum (FBS, heat inactivated) were purchased from Sigma-Aldrich Chemicals, Saint Louis, MO, USA. Phosphate-buffered saline (PBS, pH 7.4) was purchased from Gibco (Life Technologies). HPLC grade dimethyl sulfoxide (DMSO) was purchased from Alfa Aesar. All of the solutions were filtered via 0.2 mM syringe filters for sterilization. OD (OD~570~) measurements were performed using a microtiter plate reader (VERSA max tunable; Molecular Devices, Sunnyvale, CA). PC-12 cells were cultured in F-12K growth media supplemented with 5% FBS, 10% horse serum, and 1% penicillin/streptomycin in a humidified atmosphere with 5% CO~2~ at 37 °C. Cells were grown in tissue-culture-treated dishes and used when 70% confluent. Just before the experiments, the media was replaced by F-12K containing 10% FBS and 1% penicillin/streptomycin. To ensure the reproducibility in monitoring Aβ self-assembly, Aβ peptides were monomerized by following Zagorski's protocol as explained elsewhere.^[@ref40],[@ref42]^ Briefly, three cycles of dissolution, sonication in TFA (predistilled), and drying under vacuum was followed by HFIP treatment. Aβ peptides were dissolved in HFIP, sonicated, and dried under nitrogen. HFIP traces were removed under high vacuum (0.5 mm Hg) for 2 h. Peptides were finally dissolved in 1 mL of HFIP and aliquoted as 100 μg stocks. Just before the experiments, an aliquot of monomerized Aβ peptide was diluted in 20 mM NaOH to a concentration of 200 μM. Aβ peptides were further diluted to 20 μM by adding 10 mM sodium phosphate buffer (SPB, pH 7.4). PC-12 cells were seeded at a rate of 17 000 cells per well per 80 μL, and incubated overnight. Test peptides dissolved in DMSO as 5 mM stock solutions were diluted to concentrations of 200, 100, and 20 μM, in PBS, immediately before the experiments. Next day, 10 μL of Aβ was taken in each well with and without the test peptides (10 μL) and incubated for 6 h. The final concentration ratios of Aβ and test peptides were kept as 1:1, 1:5, and 1:10. After 6 h, MTT (20 μL, 5 mg/mL in PBS) was added and further incubated for 4 h. The plates were centrifuged for 10 min at 4 °C. After removing the supernatant carefully, DMSO (200 μL, per well) was added. The suspension was well-mixed and OD~570~ were measured. Untreated cell samples were taken as control. Setting the ODs of untreated cell samples to 1, the cell viability was considered as 100. Corresponding percentage cell viabilities were calculated for the cell samples treated with Aβ alone or plus the test peptides. Using the formula, 100 × \[OD~570~ (test peptide with Aβ~1--42~) -- OD~570~ (Aβ~1--42~)\]/\[OD~570~ (control) -- OD~570~ (Aβ~1--42~)\], percentage inhibition of Aβ toxicity by each tetrapeptide was calculated. Statistical analysis was performed by the one-way ANOVA test followed by Dunnett's multiple comparison test (^\$^*p* \< 0.05, ^\#^*p* \< 0.01, \**p* \< 0.001, vs Aβ) using software GraphPad Prism, ISI, San Diego, CA. *p* Values less than 0.05 were considered as significant.

Cytotoxicity Assay {#sec4.5}
------------------

PC-12 cells were seeded in 96-well plates, @ 17 000 cells per well per 90 μL, and incubated overnight. Next day, 10 μL of 200 μM (DMSO/PBS in 1:10 ratio) inhibitor tetrapeptide **20** was added to make a final nominal concentration of 20 μM. After 6 h of incubation, 20 μL of MTT (5 mg/mL in PBS) was added and incubated further for 4 h. The plate was centrifuged for 10 min at 4 °C. Next, the supernatant was carefully discarded and DMSO was added (200 μL, per well). The suspension was mixed well and ODs (OD~570~) were measured using a microtiter plate reader. Experiments were performed in triplicates (*n* = 3) and ODs were averaged. OD of untreated cell samples was set to 1 and background ODs were subtracted from each sample OD. MTT reduction (%) in the presence of test peptides was determined by comparing the OD~570~ of each test sample to the OD~570~ of the control.

ThT Fluorescence Assay {#sec4.6}
----------------------

Because ThT shows enhanced fluorescence signal upon binding to protein aggregates, it is quite useful in the quantitative measurement of the presence of Aβ aggregates.^[@ref44]^ ThT and black, clear-bottom, 96-well plates were purchased from Sigma-Aldrich Chemicals, Saint Louis, MO, USA. Presterilization was effected via filtration using 0.2 μm syringe filters. Fluorescence measurements were performed on Tecan M200 plate reader. Aβ~1--42~ and Aβ~1--40~ were taken as 2 and 10 μM, respectively, and the tetrapeptides **20**, **24**, and **25** were taken in ratios of 1:1, 1:5, and 1:10 (Aβ/test peptides). The incubation periods for Aβ~1--42~ and Aβ~1--40~ were 24 and 72 h, respectively. Aβ~1--42~ dissolved in 20 mM NaOH (400 μM) was further diluted to 20 μM in SPB (pH 7.4). ThT (2.5 μM) dissolved in glycine--NaOH buffer (pH 8.5) was added (120 μL) in each well of a black, clear-bottom 96-well plate. Tetrapeptides **20**, **24**, and **25** (5 mM in DMSO) were diluted in PBS to 200, 100, and 20 μM set of concentrations. Aβ~1--42~ (15 μL) was added to each well followed by test peptides (15 μL) to obtain a ratio of 1:1, 1:5, and 1:10. With mechanical shaking at 200 rpm, the plate was incubated at 37 °C for 24 h. After incubation, the plates were read at wavelengths of 445 nm (λ~ex~) and 485 nm (λ~em~). The enhancement in the ThT fluorescence shown by Aβ~1--42~ comparative to blank was taken as 100%, and fluorescence values were calculated for inhibitor peptide samples co-incubated with Aβ~1--42~. Inhibition activity was calculated by the relative percent enhancement in the fluorescence of the amyloid-bound ThT fluorescence of the target--inhibitor mixture compared with that in the absence of the inhibitor. Table S1 ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01522/suppl_file/ao8b01522_si_001.pdf)) shows the inhibition (%) of aggregation in the presence of the inhibitor tetrapeptides against Aβ~1--42~. In the time-dependent study performed on the tetrapeptide **20**, the increase in ThT fluorescence upon incubation with Aβ~1--42~ relative to ThT alone (control) was taken as 100% and the RFU values were normalized for the co-incubated inhibitor peptide **20** with the Aβ~1--42~. The fluorescence observed in the blank wells was subtracted from that of test samples. Statistical analysis was performed by a one-way ANOVA test followed by Dunnett's multiple comparison test (^\$^*p* \< 0.05, ^\#^*p* \< 0.01, \**p* \< 0.001, vs Aβ) using software GraphPad Prism, ISI, San Diego, CA. *p* Values less than 0.05 were considered as significant.

Circular Dichroism Spectroscopy {#sec4.7}
-------------------------------

Calibration of the instrument, JASCO, J-815 CD spectrometer was performed by using freshly prepared (0.6 w/v %) ammonium salt of (+)-camphor-10-sulfonic acid. CD spectra were recorded using a 1 mm quartz cell in the wavelength range of 190--260 nm at 37 °C. Data points were collected at a speed of 50 nm per min with 0.2 nm intervals, a response time of 1 s and a band width of 2 nm. The data are presented as an average of 3 scans recorded in succession. Aβ~1--42~ predissolved in 20 mM NaOH (200 μM) was diluted in SPB to 20 μM. Inhibitor peptide **20** (1.0 mM in TFE) was made up to 100 μM by diluting in SPB. To obtain a concentration ratio of 1:5 (Aβ~1--42~/**20**), 500 μL of each of Aβ~1--42~ and peptide **20** were mixed and incubated for 12 h (*t*~12h~) at 37 °C. To determine final CD spectra, a buffer blank spectrum was subtracted from that acquired for the samples. Noise was reduced by smoothing the far-UV CD spectra. The direct CD measurements (θ, in mdeg) were converted to molar ellipticity, using \[θ\] = θ/(10·*C*·*l*), where *C* and *l* denotes the molar concentration (mol/L) and path length, respectively. The molar ellipticity \[θ\] is expressed in units of deg cm^2^ dmol^--1^. Data were average of at least three scans recorded in parallel for each run sample. Spectra manager II was used for deconvolution of CD spectra and various forms of secondary structures (%) were estimated.

Transmission Electron Microscopy {#sec4.8}
--------------------------------

HRTEM and STEM investigations were performed using FEI Tecnai (G2 F20) transmission electron microscope operating at 120 keV. Glutaraldehyde (EM grade) and uranyl acetate were purchased from Sigma-Aldrich chemicals, Saint Louis, MO, USA. Carbon-coated copper grids (200 mesh) were purchased from Electron Microscopy Sciences. An aliquot of Aβ~1--42~ peptide (500 μM in 20 mM NaOH) was diluted to 50 μM in 10 mM SPB (pH 7.4). Stock solutions of tetrapeptides (5 mM in DMSO) **20** and **43** (negative control), were diluted to a final concentration of 250 μM in SPB. Equal volumes (25 μL) of Aβ~1--42~ and tetrapeptides **20** and **43** were mixed for a concentration ratio of 1:5 (Aβ~1--42~/test peptides) and incubated at 37 °C for 72 h. After the incubation period, a droplet of the sample was fixed on the grid by using 0.5% of glutaraldehyde solution. After washing by ultrapure water, grids were stained negatively by 2% uranyl acetate. The samples were air-dried and examined. Aβ~1--42~ alone plus the buffers in similar concentration was considered as a control. For unbiased classification of fibril morphology and abundance, each EM grid was investigated at various (\>10) positions.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.8b01522](http://pubs.acs.org/doi/abs/10.1021/acsomega.8b01522).NMR spectra (^1^H and ^13^C), HPLC chromatograms of the synthesized representative tetrapeptides, and bar graph representation (Figure S63) of PC-12 cell viability under test conditions ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b01522/suppl_file/ao8b01522_si_001.pdf))
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